Study of SAM486A in Cancer Patients
Author Information
Author(s): Paridaens R, Uges D R A, Barbet N, Choi L, Seeghers M, Graaf W T A van der, Groen H J M, Dumez H, Buuren I Van, Muskiet F, Capdeville R, Oosterom A T van, Vries E G E de
Primary Institution: Universitair Ziekenhuis Gasthuisberg
Hypothesis
Inhibition of polyamine synthesis may be a potential target for anticancer therapy.
Conclusion
The study found that while SAM486A was administered safely, no objective remission was observed in the cancer patients.
Supporting Evidence
- SAM486A is a new inhibitor of the polyamine biosynthetic enzyme S-adenosylmethionine decarboxylase (SAMDC).
- Preclinical testing showed promising antiproliferative activity for SAM486A.
- Doses were escalated without toxicity in 24 patients up to 400 mg m–2 cycle–1.
Takeaway
Doctors tested a new drug called SAM486A on cancer patients, but it didn't help them get better.
Methodology
SAM486A was given as a 120-hour infusion every four weeks, with dose escalation in patients with advanced cancer.
Limitations
No objective remission was seen, and the study was limited to a small sample size of patients with advanced disease.
Participant Demographics
Adult cancer patients with advanced/refractory disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website